Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is well-positioned in the rare kidney disease market with its flagship product, Filspari, showing strong demand in both the IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) indications. The recent approval of Voyxact, a competitor drug in the same market, is not expected to displace Filspari, but rather add to the overall market and potential synergies with Filspari. The extension of our Filspari IgAN exclusivity to October 2037, as well as the potential for a similar extension for FSGS, address key concerns from bears and significantly increase the net present value of our model. Given the strength of the product and its potential for continued growth, we maintain our positive outlook and Outperform rating on Travere Therapeutics' stock.

Bears say

Travere Therapeutics is currently facing multiple negative catalysts, including potential failures in upcoming earnings, ongoing legal struggles surrounding their flagship product Filspari, and potential competition from larger companies such as AZN, NVS, and VRTX in the rare-nephrology space. Additionally, the company's sole reliance on Filspari for revenue may pose a risk if the drug fails to meet expectations. These factors, coupled with high financial expectations and an uncertain pipeline with a Phase 3 drug expected in 2027, lead to a negative outlook on the stock's future performance.

Travere Therapeutics (TVTX) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 12 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.